Patents by Inventor Maripat Corr

Maripat Corr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220305121
    Abstract: Bis-aryl sulfonamide compounds and methods of using those compounds, e.g., in a method of enhancing or prolonging an immune response, are provided. For example, the compounds may be employed with a vaccine and optionally at least one other adjuvant and/or one or more TLR ligands, at least one MAP kinase inhibitor, or any combination thereof.
    Type: Application
    Filed: August 15, 2020
    Publication date: September 29, 2022
    Inventors: Dennis A. Carson, Tomoko Hayashi, Maripat Corr, Howard B. Cottam, Nijunj Shukla, Michael Chan
  • Publication number: 20150366962
    Abstract: This disclosure relates to compositions and methods useful to augment an immune response and methods and compositions for inducing immunogenicity to influenza antigens.
    Type: Application
    Filed: June 20, 2015
    Publication date: December 24, 2015
    Inventors: Dennis A. Carson, Howard B. Cottam, Tomoko Hayashi, Maripat Corr, Peter Palese, Peter Goff
  • Patent number: 7713526
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: May 11, 2010
    Assignee: The Regents of the University of California
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
  • Patent number: 7682607
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: March 23, 2010
    Assignee: The Regents of the University of California
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
  • Publication number: 20040203003
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Application
    Filed: March 5, 2004
    Publication date: October 14, 2004
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M Leoni, Maripat Corr, Dennis A Carson
  • Publication number: 20030165500
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Application
    Filed: November 1, 2002
    Publication date: September 4, 2003
    Applicant: REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
  • Publication number: 20030044409
    Abstract: This invention is in the field of immunology. More specifically, it relates to compositions and methods for identifying, treating and preventing cancer by targeting the extracellular domains of the frizzled receptor family of proteins.
    Type: Application
    Filed: May 1, 2001
    Publication date: March 6, 2003
    Inventors: Dennis A. Carson, Maripat Corr, Chae-Seo Rhee, Lorenzo M. Leoni, Malini Sen